{
    "ticker": "BVS",
    "name": "Biospecifics Technologies Corp.",
    "description": "Biospecifics Technologies Corp. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions. Founded in 1981, the company specializes in the research and development of proprietary collagenase products for various medical applications. Its flagship product, XIAFLEX, is a collagenase enzyme therapy approved for the treatment of Dupuytren's contracture and Peyronie's disease. Biospecifics aims to address unmet medical needs with its unique and effective therapies, leveraging its extensive expertise in collagenase technology. The company collaborates with leading pharmaceutical companies to expand the indications of its products and enhance patient outcomes. With a commitment to scientific innovation and patient-centric solutions, Biospecifics is dedicated to improving the quality of life for patients suffering from fibrotic diseases and related conditions. The company's mission is to drive advancements in collagenase therapy while ensuring the highest standards of safety and efficacy in its products.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Lynbrook, New York, USA",
    "founded": "1981",
    "website": "https://www.biospecifics.com",
    "ceo": "Thomas S. Schall",
    "social_media": {
        "twitter": "https://twitter.com/Biospecifics",
        "linkedin": "https://www.linkedin.com/company/biospecifics-technologies-corp/"
    },
    "investor_relations": "https://www.biospecifics.com/investor-relations",
    "key_executives": [
        {
            "name": "Thomas S. Schall",
            "position": "CEO"
        },
        {
            "name": "Daniel L. Cohen",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "XIAFLEX"
            ]
        }
    ],
    "seo": {
        "meta_title": "Biospecifics Technologies Corp. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Biospecifics Technologies Corp., a leader in biopharmaceuticals focused on collagenase products for fibrotic conditions. Discover XIAFLEX and its impact on patient care.",
        "keywords": [
            "Biospecifics",
            "XIAFLEX",
            "Collagenase",
            "Biopharmaceuticals",
            "Healthcare"
        ]
    },
    "faq": [
        {
            "question": "What does Biospecifics Technologies focus on?",
            "answer": "Biospecifics Technologies focuses on the development of collagenase products for therapeutic applications."
        },
        {
            "question": "What is XIAFLEX?",
            "answer": "XIAFLEX is a collagenase enzyme therapy used to treat Dupuytren's contracture and Peyronie's disease."
        },
        {
            "question": "Where is Biospecifics headquartered?",
            "answer": "Biospecifics is headquartered in Lynbrook, New York, USA."
        },
        {
            "question": "When was Biospecifics founded?",
            "answer": "Biospecifics was founded in 1981."
        }
    ],
    "competitors": [
        "THRX",
        "SAGE",
        "AMGN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}